Fast-Track Your Viral Vector Therapy with Scalable & Cost-Effective Solutions
Unleash the full potential of your viral vector-based therapies with Exothera’s advanced manufacturing platform, exoREADY. From early-stage process development to full-scale commercial production, we provide tailored solutions to accelerate your therapy’s journey to market—without compromising quality.
Your Trusted Partner for Viral Vector Manufacturing
Backed by decades of experience, our expert team delivers robust, scalable, and cost-effective manufacturing solutions for viral vectors, including AAV, adenovirus, lentivirus, influenza, polio, and herpes virus. Whether you require adherent or suspension cell culture processes, our integrated approach streamlines your therapy’s development and ensures seamless transition to commercial-scale production.
We support you at every step of your product’s lifecycle, optimizing both upstream and downstream processes to maximize efficiency, yield, and quality.
With extensive GMP, Quality Control (QC), and Quality Assurance (QA) experience, Exothera ensures compliance with global regulatory standards. Our GMP-certified facility enables the production of custom viral vector products from preclinical to commercial scale.
Tailored Viral Vector Solutions to Overcome Manufacturing Challenges
Scalability
Exothera leverages industry-leading platforms, including scale-X™ bioreactors from Univercells Technologies and iCELLis® bioreactors from Pall Corporation, ensuring predictable and seamless scale-up from R&D to GMP production.
- Fixed-Bed Bioreactors: Ideal for adherent cell culture, enabling high cell density and productivity.
- Adherent platform: From 10m² up to 600m²
- Stirred-Tank & Wave Bioreactors: Single-use suspension bioreactors for flexible and scalable viral vector production.
- Suspension platform: From 10L to 200L and even up to 2000L
Efficiency & Cost-Effectiveness
Our advanced bioreactor platforms are designed to optimize yield while reducing footprint, time, and cost. The scale-X™ technology enhances process intensification, enabling higher productivity with lower operational costs. Our stirred tank platform provides the scalability and flexibility needed to efficiently meet clinical and commercial demands, without compromising on quality or cost control.
Product Quality & Consistency
We integrate state-of-the-art purification and analytics to ensure high-quality viral vector production. Our robust single-use downstream processing (DSP) solutions—including chromatography, filtration, and formulation—help maintain the highest purity and potency for your therapy.
Regulatory & CMC Support
Navigating regulatory pathways can be complex, but our team is here to support you. Exothera provides comprehensive CMC consulting to facilitate regulatory submissions and increase your therapy’s chances of approval.
We also offer
- GMP banking services, including MCB, MVS, WCB, and WVS
- Stability studies on Drug Substance and Drug Product
- Fill & Finish capabilities
- Storage solutions for your product
- Ability to work with HQ Grade or GMP Plasmid
Viral Vector Manufacturing Platforms
Upstream Processing: Scalable Bioreactor Technologies
Fixed-Bed Bioreactors
scale-X™ Bioreactors (Univercells Technologies)
Featuring a structured and intensified fixed-bed design, scale-X™ bioreactors are chained with in-line product concentration. They offer predictable scalability from R&D to GMP while accommodating a range of viral targets, offering the flexibility and performance essential to a CDMO.
Benchtop: 10–30 m²
NevoLine: 200–600 m²
iCELLis® 500+ (Pall Corporation)
Up to 500 m²
Suspension-Based Bioreactors
Our suspension-based manufacturing platform are established on a range of different sizes stirred tank single-use bioreactors from Pall Corporation, including Allegro™ STR single-use bioreactors series. These bioreactors deliver consistent and scalable cell culture performance across the range. From the outset of the design, our technology places strong emphasis toward providing a compact, ergonomic and intuitive turnkey bioreactor design concept to maximize usability and process assurance, while maintaining optimal performance needed in a cell culture environment through several easy and intuitive operation features.
Sartorius Wave Bioreactors: RM 50 & RM 200 (70–200 L)
Allegro™ STR Single-Use Bioreactors (Pall Corporation):
200 L
2000 L
Downstream Processing: Purification & Formulation
Our DSP platforms ensure high-purity viral vectors with a range of advanced technologies:
Chromatography & Filtration
ÄKTA Pilot
ÄKTA Ready
ÄKTA Readyflux
Buffer Preparation & Formulation
Pall Lev Mixer (200 L)
Pall Allegro Cubic Mixer
Repligen KrosFlo
Pall Allegro MVP Advanced
Looking for more information?
Speak to our Business Development Team and let’s discuss how Exothera’s Viral Vector platform can empower your next breakthrough!
Speak to our Business Development Team:
Adam Thakore
Business Development Manager for Western EU, UK and PacAsia
Oliver Dezutter
Business Development Manager for Eastern Europe
Gavin Allsop
Head of Business Development and Senior Director Northern America at Exothera